Humanoid Series A, Atoms $1.7bn raise and biotech seed rounds announced
Series A for Humanoid, a $1.7bn raise by Atoms, a SoftBank loan for ABB robotics, and seed funding for Phoenix Lab and Colossal Biosciences highlight recent capital moves in robotics and biotech.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Robotics
Humanoid secured a $152 million Series A at a $1.35 billion post‑money valuation, bringing total capital raised to $270 million. The round was led by Prime Movers Lab with participation from Schaeffler, Bosch, Fubon Financial Holding Venture Capital and Aglaé Ventures, and also featured a strategic commercial agreement with Schaeffler for the deployment of thousands of robots. Proceeds will fund the next‑generation humanoid platform, mass‑manufacture of wheel‑based robots, and beta deployments in logistics, manufacturing and retail from Q4 2026, while expanding its proprietary KinetIQ AI stack and partnerships with SAP, Nvidia, Siemens and others [2][3][4][1].
SoftBank arranged a $1.75 billion syndicated debt facility – $800 million in dollars and €825 million in euros – priced at a 4.25 percentage‑point margin and sold at 98.5 cents on the dollar. The loan, underwritten by BNP Paribas, Goldman Sachs, HSBC and Mizuho, is earmarked to finance SoftBank’s $5.4 billion acquisition of ABB’s industrial robotics division. The facility expands the dollar tranche by $200 million, reflecting strong investor appetite for leveraged‑loan exposure to automation hardware as labour costs rise and supply‑chain reshoring drives demand for industrial robots [6].
Genetic Engineering
Phoenix Lab, the AI‑driven drug‑discovery startup spun out of SK Networks and Stanford talent, closed an $8 million seed round led by Menlo Ventures under its Cheiron vehicle. Investors also included Chai Discovery CEO Josh Meyer, former Starbucks and Reckitt chief Laxman Narasimhan, and former Apple AI head John Giannandrea, while the advisory board features MIT professor Robert Langer and ex‑Pfizer CMO Freda Lewis‑Hall. The funding will enhance the company’s Life Sciences Knowledge Graph, broaden clinical, regulatory and strategic workflow capabilities, and support talent acquisition for engineering, product and life‑sciences teams, building on early adoption by Boryung, Hanmi, Dong‑A and GC Green Cross [5].